News Center
Share the latest news with you
IMPACT Entered into Commercial Partnership with Huadong Medicine

SHANGHAI, China, December 20, 2023 - IMPACT Therapeutics ("IMPACT"), a biopharmaceutical company focusing on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality, and Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd, a subsidiary of Huadong Medicine Co., Ltd (SZ.000963) (collectively, "Huadong Medicine") today announced that IMPACT and Huadong Medicine have entered into an agreement for promoting Senaparib, a novel PARP inhibitor.

Under the collaboration agreement, Huadong Medicine receives exclusive promotion rights of Senaparib in mainland China. IMPACT will continue to be responsible for development, registration, manufacturing, supply, and distribution of Senaparib.

"We are very excited to collaborate with Huadong Medicine. This partnership will maximize the market potential of Senaparib in China. Senaparib is expected to be marketed for first-line maintenance therapy for patients with advanced ovarian cancer with Best-in-Class potential regardless of BRCA mutation status." said Sui Xiong Cai, Chief Executive Officer of IMPACT. "Leveraging Huadong Medicine's commercial footprint and extensive experiences in promoting novel therapeutics, we believe this partnership will translate the clinical value of Senaparib into benefiting more cancer patients."

"IMPACT has a solid research and development platform. The new drug application for Senaparib in China had been accepted by National Medical Products Administration in August 2023, and this program synergizes well with the existing ovarian cancer pipeline at Huadong Medicine." said Liang Lv, Chairman of the Board and General Manager of Huadong Medicine. "We are delighted to establish the partnership with IMPACT, commercializing Senaparib in China and bringing more efficacious, and better tolerated therapeutic options to ovarian cancer patients."

Under the terms of the agreement, IMPACT will receive an upfront payment of CNY 100 million and will be eligible to receive up to CNY 190 million upon the achievement of certain regulatory and commercial milestones. Huadong Medicine will receive promotion service fees on net sales.

About Senaparib
Senaparib, discovered and developed by IMPACT, is a potent and novel PARP1/2 inhibitor. Its distinctive molecular structure ensures exceptional target selectivity and wide therapeutic window. The Phase Ⅲ registrational study (FLAMES) evaluating Senaparib as a first-line maintenance therapy in advanced ovarian cancer patients (all-comers) has met its primary endpoint. In August 2022, the fixed dose combination capsules of Senaparib and temozolomide for the treatment of adult patients with small cell lung cancer was granted orphan-drug designation by the U.S. Food and Drug Administration (FDA). In August 2023, the National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for Senaparib in China.

About IMPACT Therapeutics
IMPACT Therapeutics is a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality. IMPACT Therapeutics has assembled one of the most comprehensive DNA damage responses (DDR) global pipeline of novel drug candidates generated by in-house discovery efforts and is expanding to other novel synthetic lethality targets to broaden its pipeline. IMPACT’s pipeline products include PARP inhibitor Senaparib (IMP4297), WEE1 inhibitor (IMP7068), ATR inhibitor (IMP9064), and PARP1 selective inhibitor (IMP1734, in collaboration with Eikon Therapeutics), as well as other novel DDR pathway inhibitors. For additional information, please visit

About Huadong Medicine
Huadong Medicine Co., Ltd. (SZ.000963) is a leading large-scale comprehensive pharmaceutical listed company based in Hangzhou, China. Founded in 1993, Huadong Medicine has fully integrated R&D, manufacturing, distribution, sales, and marketing capabilities. Huadong Medicine's product portfolio and pipeline are specialized in oncology, immunology, nephrology, and diabetes. Huadong Medicine has over 14,000 employees and highly extensive commercial coverage and marketing capabilities in China. 'Patient Centered, Science Driven' is Huadong Medicine's value. For additional information, please visit

IMPACT Therapeutics Contact:
+86 21 6841 1121
Huadong Medicine Contact:
+86 571 8990 3300

News Recommendation